Therapeutic news in ALS - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Revue Neurologique Year : 2021

Therapeutic news in ALS


Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by death of motor neurons in the cortex and the spinal cord. This loss of motor neurons causes progressive weakness and amyotrophy. To date, the median duration of survival in patients with ALS, from first symptoms to death, is estimated to be 36 months. Currently the treatment is limited to two options: riluzole which prolongs survival for a few months and edaravone which is available in only a few countries and also has a small impact on disease progression. There is an urgent need for more effective drugs in this disease to significantly improve progression. Over the last 30 years, all trials have failed to find a curative drug for ALS. This is due, partially, to the heterogeneity of the clinical features and the pathophysiology of motor neuron death. We present in this review the various treatment options currently being developed for ALS, with an emphasis on the range of therapeutic approaches being explored, from old drugs tested in a new indication to innovative drugs obtained via biotechnology or gene therapy.
Fichier principal
Vignette du fichier
S0035378721004641.pdf (1.07 Mo) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03331917 , version 1 (24-05-2023)




Philippe Corcia, Stéphane Beltran, Salah Eddine Bakkouche, Philippe Couratier. Therapeutic news in ALS. Revue Neurologique, 2021, 177 (5), pp.544-549. ⟨10.1016/j.neurol.2020.12.003⟩. ⟨hal-03331917⟩
34 View
38 Download



Gmail Mastodon Facebook X LinkedIn More